Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

Dupilumab reduces COPD exacerbations and Type 2 inflammation biomarkers, with strongest benefit in patients with high ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Patients with asthma and allergic bronchopulmonary aspergillosis experienced improvements with dupilumab, according to data ...

Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, according to a retrospective study.

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Discover a study that highlights dupilumab’s consistent efficacy in eosinophilic oesophagitis, even among patients with ...

Dupilumab (Dupixent; Sanofi/Regeneron) has been approved to treat moderate to severe AD in children aged 6 months and older as well as in children who have asthma and eosinophilic esophagitis.

Dupilumab, a fully human monoclonal antibody that blocks the interleukin-4 and interleukin-13 pathways, is approved for the treatment of five diseases marked by type 2 inflammation that are often ...

Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than ...

Dupilumab (Dupixent), a medicine that you get as a shot, is the first new treatment for CSU in the U.S. in over a decade. It’s already used to treat different inflammation conditions in the U.S ...

In a post-hoc analysis, dupilumab improved symptoms of atopic dermatitis (AD) in young children ages 6 months to 5 years. Youngsters with associated comorbidities such as asthma, allergic rhinitis ...